Evidence map›Paper›PMID 32398040›Full record

ArticleBMC cancer2020

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.

A De Bruycker, A Spiessens, P Dirix, N Koutsouvelis, I Semac, N Liefhooghe, A Gomez-Iturriaga, W Everaerts, F Otte, A Papachristofilou and 15 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03569241 (PEACE V), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03569241 phase2active not recruitingnot on this map

PEACE V: a Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

TypeinterventionalSponsorUniversity Hospital, GhentRan2018 to 2026Enrolled196ConditionsProstate Cancer, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic CancerArmswhole pelvic radiotherapy, metastasis-directed treatment, salvage Lymph Node Dissection, androgen deprivation therapy
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. [Salvage lymphadenectomy for recurrent prostate cancer].Urologie (Heidelberg, Germany) · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 19 institutions in 6 countries.

A De BruyckerDepartment of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium.
A SpiessensDepartment of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium.
P DirixDepartment of Radiation oncology, Iridium Cancer Network, GZ Antwerp, Antwerp, Belgium.
N KoutsouvelisDepartment of Radiation oncology, Geneva University Hospital, Geneva, Switzerland.
I SemacDepartment of Radiation oncology, Geneva University Hospital, Geneva, Switzerland.
N LiefhoogheDepartment of Radiation oncology, AZ Groeninge, Kortrijk, Belgium.
A Gomez-IturriagaCruces University Hospital (Biocruces Health Research Institute), Barakaldo, Spain.
W EveraertsDepartment of Development and Regeneration, KU Leuven, Leuven, Belgium.
F OtteDepartment of Radiation oncology, Jules Bordet Institute and Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.
A PapachristofilouClinic of Radiotherapy & Radiation Oncology, University Hospital Basel, Basel, Switzerland.
M ScorsettiHumanitas Clinical and Research Hospital, IRCSS, Radiotherapy and Radiosurgery Department, Rozzano, Milan, Italy.
M ShelanDepartment of Radiation oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
S SivaEpworth Healthcare, University of Melbourne, Melbourne, Australia.
F AmeyeDepartment of Urology, AZ Maria-Middelares Ghent, Ghent, Belgium.
M GuckenbergerDepartment of Radiation Oncology, University Hospital Zürich, University of Zurich, Zürich, Switzerland.
R HeikkiläDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
P M PutoraDepartment of Radiation oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
A ZapateroUniversity Hospital La Princesa, Madrid, Spain.
A Conde-MorenoDepartment of Radiation oncology, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
F CouñagoDepartment of Radiation oncology, University Hospital of Quirón, Madrid, Spain.
F VanhoutteDepartment of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium.
E GoetghebeurDepartment of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.
D ReyndersDepartment of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.
T ZilliDepartment of Radiation oncology, Geneva University Hospital, Geneva, Switzerland. Thomas.Zilli@hcuge.ch.
P OstDepartment of Radiation oncology and experimental cancer research, Ghent University Hospital, Ghent, Belgium. piet.ost@ugent.be.
Ghent University Hospital · BEUniversity Hospital of Geneva · CHGhent University · BEAZ Groeninge · BEAZ Maria Middelares · BEHospital de Cruces · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario de La Princesa · ESHospital Universitario Quirónsalud Madrid · ESIRCCS Humanitas Research Hospital · ITIridium Kankernetwerk · BEKU Leuven · BEOslo University Hospital · NOThe University of Melbourne · AUUniversité Libre de Bruxelles · BEUniversity Hospital of Basel · CHUniversity Hospital of Bern · CHUniversity of Bern · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPelvic nodal recurrences are being increasingly diagnosed with the introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the restaging of recurrent prostate cancer (PCa). At this moment, there are no specific treatment recommendations for patients with limited nodal recurrences and different locoregional treatment approaches are currently being used, mostly by means of metastasis-directed therapies (MDT): salvage lymph node dissection (sLND) or stereotactic body radiotherapy (SBRT). Since the majority of patients treated with MDT relapse within 2 years in adjacent lymph node regions, with an estimated median time to progression of 12-18 months, combining MDT with whole pelvic radiotherapy (WPRT) may improve oncological outcomes in these patients. The aim of this prospective multicentre randomized controlled phase II trial is to assess the impact of the addition of WPRT to MDT and short-term androgen deprivation therapy (ADT) on metastasis-free survival (MFS) in the setting of oligorecurrent pelvic nodal recurrence. METHODS &

designPatients diagnosed with PET-detected pelvic nodal oligorecurrence (≤5 nodes) following radical local treatment for PCa, will be randomized in a 1:1 ratio between arm A: MDT and 6 months of ADT, or arm B: WPRT added to MDT and 6 months of ADT. Patients will be stratified by type of PET-tracer (choline, FACBC or PSMA) and by type of MDT (sLND or SBRT). The primary endpoint is MFS and the secondary endpoints include clinical and biochemical progression-free survival (PFS), prostate cancer specific survival, quality of life (QoL), toxicity and time to castration-resistant prostate cancer (CRPC) and to palliative ADT. Estimated study completion: December 31, 2023. DISCUSSION: This is the first prospective multicentre randomized phase II trial assessing the potential of combined WPRT and MDT as compared to MDT alone on MFS for patients with nodal oligorecurrent PCa.

trial registrationClinicalTrials.gov Identifier: NCT03569241, registered June 14, 2018, ; Identifier on Swiss National Clinical Trials Portal (SNCTP): SNCTP000002947, registered June 14, 2018.

Indexed as

Androgen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalProstatic NeoplasmsRadiosurgerySalvage TherapyAdolescentAdultAgedAged, 80 and overClinical Trials, Phase II as TopicCombined Modality TherapyFollow-Up StudiesHumansMaleMiddle AgedAndrogen AntagonistsAndrogen deprivation therapyMetastasis-directed therapyOligometastasesOligorecurrenceProstate cancerQuality of lifeSalvage lymph node dissectionStereotactic body radiotherapySurvivalWhole pelvic radiotherapy

Identifiers

PMID32398040
PMCPMC7216526
OpenAlexW3024645857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.